Cosmetic-Drug Ingredient Review Deferral To CIR Suggested By Attorney
This article was originally published in The Tan Sheet
Executive Summary
FDA should refer the review of cosmetic-drug ingredients to independent Cosmetic Ingredient Review panel rather than spend extended periods developing drug monographs, consultant David Steinberg (Steinberg & Associates) said at a public hearing on OTC drug regulation in Gaithersburg, Md. June 28-29.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning